Cathay Biotech Inc.

Shanghai Stock Exchange 688065.SS

Cathay Biotech Inc. Shareholders' Equity for the year ending December 31, 2023: USD 1.57 B

Cathay Biotech Inc. Shareholders' Equity is USD 1.57 B for the year ending December 31, 2023, a -0.89% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Cathay Biotech Inc. Shareholders' Equity for the year ending December 31, 2022 was USD 1.59 B, a -5.47% change year over year.
Cathay Biotech Inc. Shareholders' Equity for the year ending December 31, 2021 was USD 1.68 B, a 5.50% change year over year.
Cathay Biotech Inc. Shareholders' Equity for the year ending December 31, 2020 was USD 1.59 B, a 138.68% change year over year.
Cathay Biotech Inc. Shareholders' Equity for the year ending December 31, 2019 was USD 666.57 M, a 45.23% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Shanghai Stock Exchange: 688065.SS

Cathay Biotech Inc.

CEO	Dr. Xiucai Liu
IPO Date	Aug. 12, 2020
Location	China
Headquarters	Building #5
Employees	1,803
Sector	Health Care
Industries Biotechnology

Description

Cathay Biotech Inc. engages in the production and sale of bio-based polyamide, bio-based DN5, long chain dibasic acids, and biobutanol. The company is headquartered in Shanghai, China.

Key trends

Past 5 years